Choi Hyoung Soo, Koh Sang Hyeok, Park Eun Sil, Shin Hee Young, Ahn Hyo Seop
Department of Pediatrics and Cancer Research Institute, Seoul National University College of Medicine, Seoul 110-744, Korea.
Pediatr Blood Cancer. 2005 Jul;45(1):68-71. doi: 10.1002/pbc.20315.
We report here central nervous system (CNS) recurrence in neuroblastoma (NBL) after CD34(+) peripheral blood stem cell transplantation (PBSCT). Fifteen stage 4 NBL patients underwent CD34(+) transplantation with myeloablative chemotherapy consisting of carboplatin, etoposide, and melphalan. There were three primary site recurrences and five distant metastases including four brain metastases (two isolated CNS recurrences) at 4-7 months after CD34(+) transplantation. Three of four patients died of CNS progressive disease at 2, 8, and 9 months after recurrence and the remaining single patient was lost to follow-up. CNS recurrence in NBL is fatal and requires identification of risk factors and more effective treatment strategies.
我们在此报告神经母细胞瘤(NBL)患者在接受CD34(+)外周血干细胞移植(PBSCT)后出现中枢神经系统(CNS)复发的情况。15例4期NBL患者接受了含卡铂、依托泊苷和美法仑的清髓性化疗联合CD34(+)移植。在CD34(+)移植后4至7个月,出现了3例原发部位复发和5例远处转移,其中包括4例脑转移(2例孤立的CNS复发)。4例患者中有3例在复发后2、8和9个月死于CNS进展性疾病,其余1例患者失访。NBL的CNS复发是致命的,需要识别危险因素并制定更有效的治疗策略。